CrownBio launches inflammatory disease models to advance research

The innovative pre-clinical models of inflammatory bowel disease and rheumatoid arthritis, mark the first of many that Crown Bioscience plans to release, as part of its commitment to serve autoimmune and inflammatory disease researchers

Crown Bioscience is a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research.

It has recently developed mechanistically diverse pre-clinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) to help inform decision making and in pre-clinical drug development.

The models have been scientifically designed to evoke the similar clinical features observed in humans suffering from these conditions, making them ideal systems for pre-clinical researchers developing IBD and RA therapeutics.

Laurie Heilmann, SVP of Global Strategy at CrownBio, said: "Millions of patients endure the pain and discomfort caused by RA and IBD. Our team led by Joel Tocker, Head of Inflammation, has more than 40 years of drug discovery experience in autoimmune and inflammatory diseases to help build ideal models that lead to therapeutic advancements."

The IBD models include, acute dextran sodium sulfate (DSS) challenge and T cell transfer models of IBD, develop symptoms indicative of IBD, including weight loss, colon shortening and an associated inflammation in the gut.

The RA models include collagen-induced arthritis and collagen antibody-induced arthritis models that develop the clinical features of arthritis including swollen and inflamed joints.

Jean Pierre Wery, CEO at CrownBio, said: "CrownBio is excited to expand the unique advantages of our scientific technology platform into autoimmune and inflammatory disease research. We look forward to growing our therapeutic portfolio in this area and delivering valuable insights, which drive new discoveries that bring drugs to market, achieving our mission of connecting science to patients."

Companies